United Therapeutics grants options to director

United Therapeutics director Christopher Patusky received a grant of 2,380 stock options on July 22, 2026, with an exercise price of $527.07 per share, expiring July 22, 2033.

Rhea-AI Filing Summary

United Therapeutics director Christopher Patusky received a grant of 2,380 stock options on July 22, 2026, with an exercise price of $527.07 per share, expiring July 22, 2033. This annual non-employee director award becomes fully vested on the earlier of the one-year anniversary of the grant date or the date of the next Annual Meeting of Shareholders, which is anticipated to be June 25, 2027. Following the grant, he directly holds 2,380 options under this award and 2,410 shares of common stock.

Insider Trade Summary

Grant/Award: 2,380 shares

Grant/Award 2 txns

Insider PATUSKY CHRISTOPHER

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F1, F2	2,380	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 2,380 contracts (Direct); Common Stock — 2,410 shares (Direct)

Footnotes (2)

1. F1. Annual non-employee director award.
2. F2. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

Key Figures

Stock options granted: 2,380 options Exercise price: $527.07 per share Option expiration: July 22, 2033 +2 more

5 metrics

Stock options granted 2,380 options Annual non-employee director stock option award granted July 22, 2026

Exercise price $527.07 per share Exercise price for the 2,380 stock options granted to director Patusky

Option expiration July 22, 2033 Expiration date of the granted stock options

Common shares held 2,410 shares Direct United Therapeutics common stock holdings after the reported transactions

Anticipated vesting reference date June 25, 2027 Anticipated date of the next Annual Meeting of Shareholders referenced in vesting terms

Key Terms

Annual non-employee director award, exercise price, Annual Meeting of Shareholders, vested

4 terms

Annual non-employee director award financial

"Footnote F1 describes an Annual non-employee director award."

exercise price financial

"Stock option has a $527.07 exercise price per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Annual Meeting of Shareholders financial

"Awards vest by the date of the next Annual Meeting of Shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

vested financial

"Annual non-employee director awards become fully vested on specified dates."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option award did United Therapeutics (UTHR) grant to director Christopher Patusky?

United Therapeutics granted Christopher Patusky 2,380 stock options on July 22, 2026. The options have an exercise price of $527.07 per share, are exercisable for common stock, and expire on July 22, 2033.

How and when do Christopher Patusky’s new United Therapeutics (UTHR) options vest?

The annual non-employee director award becomes fully vested on the earlier of the one-year anniversary of the July 22, 2026 grant or the date of the next Annual Meeting of Shareholders, which is anticipated to be June 25, 2027.

What is the exercise price of Christopher Patusky’s United Therapeutics (UTHR) stock options?

The stock options carry an exercise price of $527.07 per share. Each option is exercisable for one share of United Therapeutics common stock, providing equity-based compensation tied directly to the company’s share price performance over time.

When do Christopher Patusky’s United Therapeutics (UTHR) stock options expire?

The granted stock options expire on July 22, 2033. After this expiration date, any unexercised options from this specific director award will lapse and can no longer be used to acquire United Therapeutics common stock.

How many United Therapeutics (UTHR) shares does Christopher Patusky hold after this option grant?

After the reported transactions, Christopher Patusky directly holds 2,410 shares of United Therapeutics common stock. He also holds 2,380 stock options under this specific director award, which are exercisable into additional common shares upon vesting.

Was Christopher Patusky’s United Therapeutics (UTHR) option grant part of routine board compensation?

Footnotes describe the transaction as an annual non-employee director award. This indicates the 2,380 stock options are part of the regular equity compensation program for non-employee directors serving on United Therapeutics’ board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:38 PM Accepted by SEC EDGAR 07/23/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATUSKY CHRISTOPHER

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								2,410	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$527.07	07/22/2026		A		2,380(1)		06/25/2027(2)	07/22/2033	Common Stock	2,380	$0.00	2,380	D

Explanation of Responses:

1. Annual non-employee director award.

2. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)